Leading personality in the company’s history: Bernard A. Siegfried dies at age 83

(SIX: SFZN) The Siegfried Group announced today that Dr. Bernard A. Siegfried, longtime principal and since 2003 Honorary Chairman of Siegfried Holding AG, has died at the age of 83 after an extended illness.

» Media Release (PDF)
» Photo (JPG)

Representing the fourth generation of the Siegfried family, Bernard A. Siegfried first joined the company in 1967. In 1977, he was elected to the Board of Directors and Chairman of the Executive Committee; in 1998 he became Chairman of the Board of Directors with executive responsibilities. At the General Shareholder Meeting in 2001, he handed off his executive responsibilities and resigned as Chairman of the Board two years later. The Board of Directors subsequently appointed him Honorary Chairman of Siegfried Holding AG.

His tenure saw many significant developments for the company that bears his name. In the beginning of the 1970s, he transformed the company by successively removing family members at the top management level. During this phase, Siegfried shares were listed on the Swiss stock exchange. In the 1980s, in-house pharmaceutical research was abandoned, and Bernard A. Siegfried subsequently positioned the company as a supplier to the global pharmaceutical industry. The company is still active in this market.

Andreas Casutt, Chairman of Siegfried's Board of Directors notes: 'Characterized by clear, ethical principles, Bernard Siegfried was an open and true entrepreneur with a keen sense for people and timely acting. His accomplishments remain the foundation of Siegfried's success today. Bernard Siegfried will always occupy a prominent place in our company's long history.'

Contact:

Peter A. Gehler, Chief Communications Officer
peter.gehler@siegfried.ch
Tel. +41 62 746 11 48
Cell +41 79 416 4116

Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen

About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2016, Siegfried reported annual sales of CHF 718 million and employs at the time being approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.